banter and General Discussion, page-9385

I think Dr. Lightner had the right idea about stem cells’ benefit for diseases, but perhaps went for the “wrong” company @Phaedrus.

As I tried to understand a bit more about what Dr. Lightner did between leaving Cleveland Clinic and ending up in Scripps, when she managed to publish a couple of papers in 2023 on, of all topics, treating respiratory failure due to Covid 19 using Exoflo by Direct Biologics on top of what she did with the few IBD trials, I realised potentially why she might not have updated the data that she should have done when she left Cleveland Clinic. I won’t go into what my conjecture is but isn’t that interesting? The even more interesting thing is Exoflo is made of exosomes which means the extraction yield is low and consequently the encapsulation agents whatever it is, is also low. I am assuming the company has a much better product but my point is, Dr. Lightner might have aligned herself with the wrong company. Would her talent have been better used by a company that has better and commercial-stage products? Who knows, but the webcast where she’s speaking should be happening on 9-10 April. Would the company care to spring her ex-Cleveland Clinic colleague who is the head of the Department of Gastroenterology a few questions about the trial?